Mass cytometry identifies imbalance of multiple immune‐cell subsets associated with biologics treatment in ankylosing spondylitis
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.15378 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Li Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing, Flow Cytometry, Immunophenotyping, Biological Products. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Open Bidding for Selecting the Best Candidates, National Key Research and Development Project.
Abstract (Originalsprache)
Objective
This study aims to comprehensively investigate immune‐cell landscapes in ankylosing spondylitis (AS) patients and explore longitudinal immunophenotyping changes induced by biological agents.
Methods
We employed mass cytometry with 35 cellular markers to analyze blood samples from 34 AS patients and 13 healthy controls (HC). Eleven AS patients were re‐evaluated 1 month (4 patients) and 3 months (7 patients) after treatment with biological agents. Flow Self‐Organizing Maps (FlowSOM) clustering was performed to identify specific cellular metaclusters. We compared cellular abundances across distinct subgroups and validated subset differences using gating strategies in flow cytometry scatter plots, visualized with FlowJo software. The proportions of differential subsets were then used for intercellular and clinical correlation analysis, as well as for constructing diagnostic models based on the random forest algorithm.
Results
In AS patients, we identified and validated nine different immune‐cell subsets compared to HC. Three subsets increased: helper T‐cell 17 (Th17), mucosa‐associated invariant T‐cell (MAIT), and classical monocytes (CM). Six subsets decreased: effector memory T‐cell (TEM), naïve B cells, transitional B cells, IL10+ memory B cells, non‐classical monocytes (NCM), and neutrophils. Treatments with biological agents could rectify cellular abnormalities, particularly the imbalance of CM/NCM. Furthermore, these subsets may serve as biomarkers for assessing disease activity and constructing effective diagnostic models for AS.
Conclusion
These findings provide novel insights into the specific patterns of immune cell in AS, facilitating the further development of novel biomarkers and potential therapeutic targets for AS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
- National Key Laboratory for Immunity and Inflammation, Shanghai, China.
- School of Medicine, Tsinghua University, Beijing, China.
- Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, China.
ORCID-Profile: Huji Xu
Förderung
- National Natural Science Foundation of China
- Open Bidding for Selecting the Best Candidates
- National Key Research and Development Project
- Shanghai Orthopedic Medical Research Center
Zitieren
APA
Lin, L., Luo, J., Cai, Y., Wu, X., Zhou, L., Li, T., Wang, X., & Xu, H. (2024). Mass cytometry identifies imbalance of multiple immune‐cell subsets associated with biologics treatment in ankylosing spondylitis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15378
Vancouver
Lin L, Luo J, Cai Y, Wu X, Zhou L, Li T, et al. Mass cytometry identifies imbalance of multiple immune‐cell subsets associated with biologics treatment in ankylosing spondylitis. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15378
BibTeX
@article{Lin2024,
author = {Lin, Li and Luo, Jing and Cai, Yue and Wu, Xin and Zhou, Ling and Li, Ting and Wang, Xiaobing and Xu, Huji},
title = {Mass cytometry identifies imbalance of multiple immune‐cell subsets associated with biologics treatment in ankylosing spondylitis},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.15378}
}
EUVIMED